Makers of over-the-counter drugs may soon pay for federal review of their products, just like pharmaceutical makers. And they’re fine with the change.

After years of discussion, the Food and Drug Administration appears poised to make that change as part of a sweeping overhaul of its regulations for OTC products. But during a stakeholder meeting on the topic Wednesday afternoon, it was clear that many specifics about the program will be foggy until Congress acts.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy